Robert W. Duggan - May 30, 2025 Form 4 Insider Report for Summit Therapeutics Inc. (SMMT)

Role
Co-Chief Executive Officer, Director, 10%+ Owner
Signature
/s/ Robert W. Duggan
Stock symbol
SMMT
Transactions as of
May 30, 2025
Transactions value $
$196,799
Form type
4
Date filed
6/2/2025, 04:55 PM
Previous filing
May 1, 2025
Next filing
Aug 19, 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
DUGGAN ROBERT W Co-Chief Executive Officer, Director, 10%+ Owner C/O SUMMIT THERAPEUTICS INC., 601 BRICKELL KEY DRIVE SUITE 1000, MIAMI /s/ Robert W. Duggan 2025-06-02 0001055919

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SMMT Common Stock Options Exercise $197K +74.5K +0.01% $2.64 556M May 30, 2025 Direct F1
holding SMMT Common Stock 31K May 30, 2025 By Spouse F2
holding SMMT Common Stock 10.2M May 30, 2025 By the Shaun Zanganeh Irrevocable Trust, with the Spouse of Reporting Person as Trustee F2
holding SMMT Common Stock 25.5M May 30, 2025 By the Mahkam Zanganeh Revocable Trust, with the Spouse of Reporting Person as Trustee F2
holding SMMT Common Stock 50K May 30, 2025 Immediate family member of Spouse F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SMMT Stock Option (right to buy) Options Exercise $0 -74.5K -100% $0.00 0 May 30, 2025 Common Stock 74.5K $2.64 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On May 30, 2025, the Reporting Person exercised an option to purchase 74,545 shares of the Issuer's common stock at an exercise price of $2.64 per share. The Reporting Person did not sell the underlying shares.
F2 The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 or for any other purpose.
F3 The option was granted on January 2, 2024. The shares underlying the option vested in four equal quarterly installments on March 31, June 30, September 30 and December 31, 2024.